We are live on ! Find out more
NVIV

InVivo Therapeutics Holdings Corp
NVIV

Delisted

NVIV was delisted on the 12th of February, 2024.

Back to rankings

21 hedge funds and large institutions have $2.4M invested in InVivo Therapeutics Holdings Corp in 2021 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 6 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,000% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 1

958% more capital invested

Capital invested by funds: $227K → $2.4M (+$2.17M)

500% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 1

91% more funds holding

Funds holding: 11 → 21 (+10)

Holders
21
Holders Change
+10
Holders Change %
+90.91%
% of All Funds
0.37%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
6
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$1.3M
2
Renaissance Technologies
Renaissance Technologies
New York
+$364K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$346K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$171K
5
VF
Virtu Financial
New York
+$167K

Top Sellers

Rank Fund Capital Flow
1
TRCT
Tower Research Capital (TRC)
New York
-$54.6K
2
Two Sigma Advisers
Two Sigma Advisers
New York
-$48K
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$1.08M +$1.3M +43,393 +160,715%
Renaissance Technologies
2
Renaissance Technologies
New York
$413K +$364K +12,148 +272%
Vanguard Group
3
Vanguard Group
Pennsylvania
$287K +$346K +11,546 New
Geode Capital Management
4
Geode Capital Management
Massachusetts
$185K +$171K +5,705 +324%
VF
5
Virtu Financial
New York
$139K +$167K +5,586 New
Northern Trust
6
Northern Trust
Illinois
$70K +$60.6K +2,021 +253%
Bank of New York Mellon
7
Bank of New York Mellon
New York
$67K +$80.4K +2,682 New
Citadel Advisors
8
Citadel Advisors
Florida
$59K +$71.1K +2,373 New
Millennium Management
9
Millennium Management
New York
$49K +$59.4K +1,982 New
Jane Street
10
Jane Street
New York
$23K +$27.8K +929 New
SWP
11
Stratos Wealth Partners
Ohio
$10K +$12K +400 New
ICM
12
IMS Capital Management
Oregon
$10K +$12.2K +406 New
SPIA
13
Steward Partners Investment Advisory
New York
$4.97K +$6K +200 New
Morgan Stanley
14
Morgan Stanley
New York
$3K +$3.57K +119 +1,983%
UBS Group
15
UBS Group
Switzerland
$2K +$1.98K +66 New
Two Sigma Advisers
16
Two Sigma Advisers
New York
– -$48K -2,364 Closed
TRCT
17
Tower Research Capital (TRC)
New York
– -$54.6K -1,821 -99%
EVM
18
Eaton Vance Management
Massachusetts
– +$60 +2 New
Wells Fargo
19
Wells Fargo
California
– +$90 +3 +50%

NVIV Hedge Fund Activity: Q1 2021 in Review

21 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in InVivo Therapeutics Holdings Corp (NVIV) for Q1 2021, worth a combined $2.4M — up 958% from $227K a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new NVIV positions and 1 closed out — a net gain of 10 holders — while 6 added to existing stakes and 1 trimmed.

The largest buyer was BlackRock, adding an estimated $1.3M. The largest seller was Tower Research Capital (TRC), cutting an estimated $54.6K.

  • 21 institutional investors held InVivo Therapeutics Holdings Corp (NVIV) as of Q1 2021, up from 11 in Q4 2020.
  • Funds reported $2.4M of InVivo Therapeutics Holdings Corp stock for Q1 2021, up 958% quarter-over-quarter.
  • 11 funds opened new InVivo Therapeutics Holdings Corp positions in Q1 2021 and 1 closed out, a net change of +10 holders.
  • The largest InVivo Therapeutics Holdings Corp buyer in Q1 2021 was BlackRock, an estimated $1.3M added.
  • The largest InVivo Therapeutics Holdings Corp seller in Q1 2021 was Tower Research Capital (TRC), an estimated $54.6K sold.

Based on aggregated 13F filings for Q1 2021.